In fact, the number of CD133+ cells ranged between 1 and 10% in claudin-low cells, reached 80% in basal-like cell lines, and were between 1 and 2% in both luminal and HER2+ cells, questioning the equivalence between CD133 levels and stem-like properties in breast tumor cells [18]. The gene discussed is ERBB2; the disease is breast neoplasm.